Paliperidone in the treatment of delirium: Results of a prospective open-label pilot trial

Acta Neuropsychiatrica

Volumn 23, Issue 4, 2011, Pages 179-183

  Yoon, Ho Kyoung ^a   Kim, Yong Ku ^a   Han, Changsu ^a   Ko, Young Hoon ^a   Lee, Heon Jeong ^a   Kwon, Do Young ^b   Kim, Leen ^a  

^a College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

delirium; DRS; MDAS; paliperidone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PALIPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DELIRIUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; SCORING SYSTEM;

EID: 79960562350     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2011.00568.x     Document Type: Article

References (27)

1. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry 1999; 156: 1-20.
2. Michaud L, Büla C, Berney A, et al., Delirium: guidelines for general hospitals. J Psychosom Res 2007; 62: 371-383.
3. Meagher DJ., Delirium: optimising management. BMJ 2001; 322: 144-149. (Pubitemid 32116194)
4. Peritogiannis V, Stefanou E, Lixouriotis C, Gkogkos C, Rizos D., Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci 2009; 63: 623-631.
5. Han C-S, Kim Y-K., A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45: 297-301. (Pubitemid 38823604)
6. Rea R, Battistone S, Fong J, Devlin J., Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy 2007; 27: 588-594. (Pubitemid 46536239)
7. Schwartz T, Masand P., The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43: 171-174. (Pubitemid 34522526)
8. Richelson E, Souder T., Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
9. Janssen Pharmaceutica Products L. Invega (paliperidone) extended-release tablets, package insert. Titusville, 2007.
10. Ozbolt L, Paniagua M, Kaiser R., Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc 2008; 9: 18-28.
11. Prakanrattana U, Prapaitrakool S., Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care 2007; 35: 714-719. (Pubitemid 47572095)
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Press, 1994.
13. Trzepacz PT, Baker RW, Greenhouse J., A symptom rating scale for delirium. Psychiatry Res 1988; 23: 89-97. (Pubitemid 18038426)
14. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S., The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997; 13: 128-137. (Pubitemid 27172870)
15. Rosen J, Sweet RA, Mulsant BH, Rifai AH, Pasternak R, Zubenko GS., The Delirium Rating Scale in a psychogeriatric inpatient setting. J Neuropsychiatry Clin Neurosci 1994; 6: 30-35. (Pubitemid 24047438)
16. Canuso C, Youssef E, Bossie C, Turkoz I, Schreiner A, Simpson G., Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008; 23: 209-215.
17. Canuso CM, Bossie CA, Turkoz I, Alphs L., Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009; 113: 56-64.
18. Marino J, Caballero J., Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008; 28: 1283-1298.
19. Tueth MJ., Emergencies caused by side effects of psychiatric medications. Am J Emerg Med 1994; 12: 212-216. (Pubitemid 24112555)
20. Tune L., The role of antipsychotics in treating delirium. Curr Psychiatry Rep 2002; 4: 209-212.
21. Tune LE., Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000; 5: 149-153.
22. Schotte A, Janssen PF, Gommeren W, et al., Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73. (Pubitemid 26112775)
23. Leysen JE, Janssen PM, Megens AA, Schotte A., Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55 (Suppl.): 5-12. (Pubitemid 24179363)
24. Megens AA, Awouters FH, Schotte A, et al., Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994; 114: 9-23. (Pubitemid 24150515)
25. Luthringer R, Staner L, Noel N, et al., A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007; 22: 299-308. (Pubitemid 47237549)
26. Miller D., Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004; 6: 3-7.
27. Vermeir M, Naessens I, Remmerie B, et al., Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36: 769-779. (Pubitemid 351468385)